small molecule

ISTURISA

OSILODROSTAT PHOSPHATE

Loss of exclusivityOctober 2035latest FDA-listed patent expiry

CompanyRecordati Rare Diseases Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	ISTURISA
Active ingredient	OSILODROSTAT PHOSPHATE
Strength	EQ 10MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	March 2020
Marketing status	DISCN

Listed patents

Patent	Expires	Type
10709691	October 2035	use U-2770
10143680	July 2035	product
8609862	January 2031	use U-2770
9434754	January 2031	substance
8314097	March 2029	substance, product
8835646	August 2026	substance, product

Regulatory exclusivity

Code	Expires
ODE-535	April 2032
ODE-286	March 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Recordati Rare Diseases Inc.